Ondansetron is a serotonin-3 receptor antagonist sold in the U.S. under 7 brand and generic names, for alcoholism. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Zofran and Dextrose in Plastic Container (application NDA020403). Other ondansetron products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Prevention of Nausea and Vomiting Associated with Initial and Repeat Courses of Emetogenic Cancer Chemotherapy (2.1) : Dilution of Ondansetron Injection in 50 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection is required before administration to adult and pediatric patients. Adults and pediatric patients 6 months of age and older: The recommended dosage is 0.15 mg/kg per dose for 3 doses (maximum of 16 mg per dose), infused intravenously over 15 minutes. Administer the first dose 30 minutes before the start of chemotherapy and subsequent doses 4 and 8 hours after the first dose. Prevention of Postoperative Nausea and/or Vomiting (2.2) : Dilution of Ondansetron Injection is not required before administration to adult and pediatric patients. See full prescribing information for the recommended dosage and administration instructions for adult and pediatric patients 1 month of age and older. Patients with Severe Hepatic Impairment (2.3) : Do not exceed a total daily dose of 8 mg. 2.1 Prevention of Nausea and Vomiting Associated with Initial and Repeat Courses of Emetogenic Chemotherapy Important Preparation Instructions Dilution of Ondansetron Injection in 50 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection is required before administration to adult and pediatric patients for the prevention of nausea and vomiting associated with emetogenic chemotherapy.…
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] QT Prolongation [see Warnings and Precautions (5.2) ] Serotonin Syndrome [see Warnings and Precautions (5.3) ] Myocardial Ischemia [see Warnings and Precautions (5.4) ] Masking of Progressive Ileus and Gastric Distension [see Warnings and Precautions (5.5) ] Chemotherapy-Induced Nausea and Vomiting : The most common adverse reactions (≥ 7%) in adults are diarrhea, headache, and fever. (6.1) Postoperative Nausea and/or Vomiting: The most common adverse reaction (≥ 10%) which occurs at a higher frequency compared with placebo in adults is headache. (6.1) The most common adverse reaction (≥ 2%) which occurs at a higher frequency compared with placebo in pediatric patients aged 1 to 24 months is diarrhea. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact AuroMedics Pharma LLC at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The following adverse reactions have been reported in clinical trials of adult…
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | 70/100 | Prescription | Solution | Generic | $0 | View → | |
| 2 | 70/100 | Prescription | Injectable |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| F;92 | 8 mg | yellow | oval | — |
| F;92 | 8 mg | yellow | oval | — |
| F;91 | 4 mg | white | oval | — |
| F;91 | 4 mg | white | oval | — |
| F;91 | 4 mg | white | oval | — |
| G;4 | 4 mg | white |
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
Ondansetron Orally Disintegrating Tablets
Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.
Glenmark Pharmaceuticals Inc., USA · Dec 30, 2025
Ondansetron ODT Tablets
Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.
Preferred Pharmaceuticals, Inc. · Nov 17, 2025
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Ondansetron Injection is contraindicated for patients known to have hypersensitivity (e.g., anaphylaxis) to this product or any of its components. Anaphylactic reactions have been reported in patients taking ondansetron [see Adverse Reactions (6.2) ] . The concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron. Patients known to have hypersensitivity (e.g., anaphylaxis) to this product or any of its components. (4) Concomitant use of apomorphine. (4 , 7.2)
Drugs Affecting Cytochrome P-450 Enzymes Ondansetron does not appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron [see Clinical Pharmacology (12.3) ] . On the basis of limited available data, no dosage adjustment is recommended for patients on these drugs. 7.2 Apomorphine Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with ondansetron is contraindicated [see Contraindications (4) ]. 7.3 Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs [see Clinical Pharmacology (12.3) ] . 7.4 Tramadol Although there are no data on pharmacokinetic drug interactions between ondansetron and tramadol, data from two small trials indicate that concomitant use of ondansetron may result in reduced analgesic activity of…
| $0 |
| View → |
| 3 | 64/100 | Prescription | Tablet | Generic | $0 | View → |
| 4 | 64/100 | Prescription | Tablet | Generic | $0 | View → |
| 5 | 64/100 | Prescription | Injectable | Generic | $0 | View → |
| 6 | 46/100 | Prescription | Injectable | Generic | $0 | View → |
| 7 | Not yet rated | Prescription | Film | Generic | $0 | View → |
| round |
| — |
| F;92 | 8 mg | yellow | oval | — |
|---|